Computational investigations of hERG channel blockers: New insights and current predictive models

Advanced Drug Delivery Reviews

Volumn 86, Issue , 2015, Pages 72-82

  Villoutreix, Bruno O ^a,b   Taboureau, Olivier ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

Arrhythmia; Computational approaches; HERG; Ligand based; QSAR; Structure based, Polymorphism; TdP

Indexed keywords

ACCIDENT PREVENTION; COMPUTATIONAL CHEMISTRY; COMPUTATIONAL METHODS; DISEASES; DRUG PRODUCTS; LIGANDS; POLYMORPHISM;

ARRHYTHMIA; COMPUTATIONAL APPROACH; HERG; QSAR; STRUCTURE-BASED;

PREDICTIVE ANALYTICS;

ASTEMIZOLE; CISAPRIDE; LIGAND; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG BLOCKER; TERFENADINE; UNCLASSIFIED DRUG; VARDENAFIL; ZIPRASIDONE;

CARDIOTOXICITY; COMPUTER MODEL; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; IN VITRO STUDY; LONG QT SYNDROME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SUDDEN DEATH; TORSADE DES POINTES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICALLY INDUCED; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER SIMULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LIGANDS; LONG QT SYNDROME; MODELS, BIOLOGICAL; POTASSIUM CHANNEL BLOCKERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937629636     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.03.003     Document Type: Review

References (174)

1. Rampe D., Brown A.M. A history of the role of the hERG channel in cardiac risk assessment. J. Pharmacol. Toxicol. Methods 2013, 68:13-22.
2. Vandenberg J.I., Perry M.D., Perrin M.J., Mann S.A., Ke Y., Hill A.P. hERG K(+) channels: structure, function, and clinical significance. Physiol. Rev. 2012, 92:1393-1478.
3. Kaplan W.D., Trout W.E. The behavior of four neurological mutants of drosophila. Genetics 1969, 61:399-409.
4. Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81:299-307.
5. Brown A.M. Drugs, hERG and sudden death. Cell Calcium 2004, 35:543-547.
6. Lepor H., Lepor N.E., Hill L.A., Trohman R.G. The QT interval and selection of alpha-blockers for benign prostatic hyperplasia. Rev. Urol. 2008, 10:85-91.
7. Witchel H.J. Drug-induced hERG block and long QT syndrome. Cardiovasc. Ther. 2011, 29:251-259.
8. Johannesen L., Vicente J., Gray R.A., Galeotti R.L., Loring Z., Garnett C.E., Florian J., Ugander M., Stockbridge N., Strauss D.G. Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin. Pharmacol. Ther. 2014, 95:501-508.
9. Glinka A., Polak S. The effects of six antipsychotic agents on QTc-an attempt to mimic clinical trial through simulation including variability in the population. Comput. Biol. Med. 2014, 47:20-26.
10. + channel. A model for bad behavior. J. Med. Chem. 2003, 46:2017-2022.
11. Wulff H., Castle N.A., Pardo L.A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov. 2009, 8:982-1001.
12. Elliott D.J., Dondas N.Y., Munsey T.S., Sivaprasadarao A. Movement of the S4 segment in the hERG potassium channel during membrane depolarization. Mol. Membr. Biol. 2009, 26:435-447.
13. Gintant G.A., Su Z., Martin R.L., Cox B.F. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol. Pathol. 2006, 34:81-90.
14. Hancox J.C., McPate M.J., ElHarchi A., Zhang Y.H. The hERG potassium channel anf hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 2008, 119:118-132.
15. Crumb W., Cavero I.I. QT interval prolongation by noncardiovascular drugs: issues and solutions for novel drug development. Pharm. Sci. Technol. Today 1999, 2:270-280.
16. Pollard C.E., Abi Gerges N., Bridgland-Taylor M.H., Easter A., Hammond T.G., Valentin J.P. An introduction to QT interval prolongation and non-clinical approaches assessing and reducing risk. Br. J. Pharmacol. 2010, 159:12-21.
17. Schmidtke P., Ciantar P.M., Theret I., Ducrot P. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules. J. Chem. Inf. Model. 2014, 54:2320-2333.
18. Du C., Zhang Y., El Harchi A., Dempsey C.E., Hancox J.C. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants. J. Mol. Cell. Cardiol. 2014, 74:220-230.
19. Luo F., Gu J., Chen L., Xu X. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the hERG channel. Mol. Biosyst. 2014, 10:2863-2869.
20. Stockbridge N., Morganroth J., Shah R.R., Garnett C. Drug safety. Dealing with global safety issues. Drug Saf. 2013, 36:167-182.
21. Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol. Ther. 2011, 129:109-119.
22. Witchel H.J. The hERG potassium channel as a therapeutic target. Expert Opin. Ther. Targets 2007, 11:321-336.
23. Villoutreix B.O., Lagorce D., Labbe C.M., Sperandio O., Miteva M.A. One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov. Today 2013, 18:1081-1089.
24. Broccatelli F., Mannhold R., Moriconi A., Giuli S., Carosati E. QSAR modeling and data mining link torsades de pointes risk to the interplay of extent of metabolism, active transport, and hERG liability. Mol. Pharm. 2012, 9:2290-2301.
25. De Bruin M.L., Pettersson M., Meyboom R.H., Hoes A.W., Leufkens H.G. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. 2005, 26:590-597.
26. Kesselheim A.S., Franklin J.M., Avorn J., Duke J.D. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. BMJ Qual. Saf. 2013, 22:727-734.
27. Shimasawa R., Ikeda M. Safety information in drug labeling: a comparison of the USA, the UK, and Japan, Pharmacoepidemiol. Drug Saf. 2013, 22:306-318.
28. Warnier M.J., Holtkamp F.A., Rutten F.H., Hoes A.W., de Boer A., Mol P.G., De Bruin M.L. Safety information on QT-interval prolongation: comparison of European Union and US drug labeling. Drug Discov. Today 2014, 19:1294-1297.
29. Bahri P., Harrison-Woolrych M. Focusing on the risk communication about medicines: why now?. Drug Saf. 2012, 35:971-975.
30. Polak S., Wisniowska B., Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J. Appl. Toxicol. 2009, 29:183-206.
31. Wood C., Williams C., Waldron G.J. Patch clamping by numbers. Drug Discov. Today 2004, 9:434-441.
32. + channels in human heart: comparison with terfenadine under physiological conditions. J. Pharmacol. Exp. Ther. 2000, 292:261-264.
33. + channel block-related cardiotoxicity by the H1 receptor-blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol. 1998, 54:113-121.
34. Moreno-Galindo E.G. Impact of the whole-cell patch-clamp configuration on the pharmacological assessment of the hERG channel: trazodone as a case example. J. Pharmacol. Toxicol. Methods 2014, 69:237-244.
35. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301:427-434.
36. Braga R.C., Alves V.M., Silva M.F., Muratov E., Fourches D., Tropsha A., Andrade C.H. Tuning HERG out: antitarget QSAR models for drug development. Curr. Top. Med. Chem. 2014, 14:1399-1415.
37. Gavaghan C.L., Arnby C.H., Blomberg N., Strandlund G., Boyer S. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J. Comput. Aided Mol. Des. 2007, 21:189-206.
38. O'Brien S.E., de Groot M.J. Greater than the sum of its parts: combining models for useful ADMET prediction. J. Med. Chem. 2005, 48:1287-1291.
39. Du F., Yu H., Zou B., Babcok J., Long S., Li M. hERGCentral: a large database to store, retrieve, and analyze compound-human ether-a-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay Drug Dev. Technol. 2011, 9:580-588.
40. Wang S., Li Y., Su L., Li D., Hou T. Recent developments in computational prediction of HERG blockage. Curr. Top. Med. Chem. 2013, 13:1317-1326.
41. Taboureau O., Jørgensen S. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target based approaches to systems chemical biology. Comb. Chem. High Throughput Screen. 2011, 14:375-387.
42. Wang S., Li Y., Wang J., Chen L., Zhang L., Yu H., Hou T. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. Mol. Pharm. 2012, 9:996-1010.
43. Czodrowski P. hERG me out. J. Chem. Inf. Model. 2013, 53:2240-2251.
44. + channel blockers. Bioorg. Med. Chem. 2004, 12:2307-2315.
45. Aronov A.M. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J. Med. Chem. 2006, 49:6917-6921.
46. Li Q., Jørgensen F.S., Oprea T., Brunak S., Taboureau O. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol. Pharm. 2008, 5:117-127.
47. Springer C., Sokolnicki K.L. A fingerprint pair analysis of hERG inhibition data. Chem. Cent. J. 2013, 7:1.
48. Doddareddy M.R., Klaasse E.C., Shagufta A.P., Bender A. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases. ChemMedChem 2010, 5:716-729.
49. Sherhod R., Judson P.N., Hanser T., Vessey J.D., Webb S.J., Gillet V.J. Emerging pattern mining to aid toxicological knowledge discovery. J. Chem. Inf. Model. 2014, 54:1864-1879.
50. Year E.R., Cleves A.E., Jain A.N. Chemical structural novelty: on-targets and off-targets. J. Med. Chem. 2011, 54:6771-6785.
51. Jain A.N., Cleves A.E. Does your model weigh the same as a duck?. J. Comput. Aided Mol. Des. 2012, 26:57-67.
52. Bento A.P., Gaulton A., Hersey A., Bellis L.J., Chambers J., Davies M., Krüger F.A., Light Y., Mak L., McGlinchey S., Nowotka M., Papadatos G., Santos R., Overington J.P. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014, 42:D1083-D1090.
53. Wang Y., Suzek T., Zhang J., Wang J., He S., Cheng T., Shoemaker B.A., Gindulyte A., Bryant S.H. PubChem Bioassay: 2014 update. Nucleic Acids Res. 2014, 42:D1075-D1082.
54. Kjærulff S.K., Wich L., Kringelum J., Jacobsen U.P., Kouskoumvekaki I., Audouze K., Lund O., Brunak S., Oprea T.I., Taboureau O. ChemProt-2.0: visual navigation in a disease chemical biology database. Nucleic Acids Res. 2013, 41:D464-D469.
55. Keiser M.J., Roth B.L., Armbruster B.N., Ernsberger P., Irwin J.J., Shoichet B.K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007, 25:197-206.
56. Filz O., Lagunin A., Filimonov D., Poroikov V. Computer-aided prediction of QT-prolongation. SAR QSAR Environ. Res. 2008, 19:81-90.
57. Gfeller D., Grosdidier A., Wirth M., Daina A., Michielin O., Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014, 42:W32-W38.
58. Liu X., Vogt I., Hague T., Campillos M. HitPick: a web server for hit identification and target prediction of chemical screenings. Bioinformatics 2013, 29:1910-1912.
59. Nickel J., Gohlke B.O., Erehman J., Banerjee P., Rong W.W., Goede A., Dunkel M., Preissner R. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014, 42:W26-W31.
60. Cheng F., Li W., Zhou Y., Shen J., Wu Z., Liu G., Lee P.W., Tang Y. admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J. Chem. Inf. Model. 2012, 52:3099-3105.
61. Zachariae U., Giordanetto F., Leach A.G. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. J. Med. Chem. 2009, 52(2009):4266-4276.
62. Keserü G.M. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg. Med. Chem. Lett. 2003, 13:2773-2775.
63. Song M., Clark M. Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model. 2006, 46:392-400.
64. Dustan Sarazan R., Crumb W.J., Beasley C.M., Emmick J.T., Ferguson K.M., Strnat C.A., Sausen P.J. Absence of clinically important hERG channel blockage by three compounds that inhibit phosphodiesterase 5-sildenafil, tadafil and vardenafil. Eur. J. Pharmacol. 2004, 502:163-167.
65. Su Z., Chen J., Martin R.L., McDermott J.S., Cox B.F., Gopalakrishnan M., Gintant G.A. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem. Pharmacol. 2006, 71:278-286.
66. Lagorce D., Maupetit J., Baell J., Sperandio O., Tuffery P., Miteva M.A., Galons H., Villoutreix M.A.B.O. FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics 2011, 27:2018-2020.
67. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. March 2001, 46(2001):3-26.
68. Hughes J.D., Blagg J., Price D.A., Bailey S., Descrescenzo G.A., Devraj R.V., Ellsworth E., Fobian Y.M., Gibbs M.E., Gilles R.W., Greene N., Huang E., Krieger-Burke T., Loesel J., Wager T., Whiteley L., Zhang Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18:4872-4875.
69. Schramm A., Baburin I., Hering S., Hamburger M. hERG channel inhibitors in extracts of Coptidis rhizoma. Planta Med. 2011, 77:692-697.
70. Schramm A., Jähne E.A., Baburin I., Hering S., Hamburger M. Natural products as potential human ether-a-go-go related gene channel inhibitors-outcomes from a screening of widely used herbal medicines and edible plants. Planta Med. 2014, 80:1045-1050.
71. Schramm A., Saxena P., Chebek J., Cahlikova L., Baburin I., Hering S., Hamburger M. Natural products as potential human ether-a-go-go related gene channel inhibitors-screening of plant-derived alkaloids. Planta Med. 2014, 80:740-746.
72. Stansfeld P.J., Gedeck P., Gosling M., Cox B., Mitcheson J.S., Sutcliffe M.J. Drug block of the hERG potassium channel: insight from modeling. Proteins 2007, 68:568-580.
73. + conduction and selectivity. Science 1998, 280:69-77.
74. + channel. Nature 2003, 423:33-41.
75. Jiang Y., Lee A., Chen J., Cadene M., Chait B.T., MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002, 417:515-522.
76. + channel Kir2.2 at 3.1A resolution. Science 2009, 326:1668-1674.
77. Chen X., Wang Q., Ni F., Ma J. Structure of the full-length Shaker potassium channel Kv1.2 by normal-mode-based X-ray crystallographic refinement. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11352-11357.
78. Anwar-Mohamed A., Barakat K.H., Bhat R., Noskov S.Y., Tyrrell D.L., Tuszynski J.A., Houghton M. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. Toxicol. Lett. 2014, 230:382-392.
79. + channel: application to ligand binding. Bioorg. Med. Chem. Lett. 2005, 15:1737-1741.
80. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12329-12333.
81. Thouta S., Sokolov S., Abe Y., Clark S.J., Cheng Y.M., Claydon T.W. Proline scan of the hERG channel S6 helix reveals the location of the intracellular pore gate. Biophys. J. 2014, 106:1057-1069.
82. + channel. J. Biol. Chem. 2009, 284:1000-1008.
83. Es-Salah-Lamoureux Z., Fougere R., Xiong P.Y., Robertson G.A., Fedida D. Fluorescence-tracking of activation gating in human ERG channels reveals rapid S4 movement and slow pore opening. PLoS One 2010, 5:e10876.
84. Dempsey C.E., Wright D., Colenso C.K., Sessions R.B., Hancox J.C. Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block. J. Chem. Inf. Model. 2014, 54:601-612.
85. + channel pore and known ligands. J. Mol. Graph. Model. 2013, 46:93-104.
86. Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., Hohnloser S.H., Shimizu W., Schwartz P.J., Stanton M., Murray K.T., Norris K., George A.L., Roden D.M. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002, 105:1943-1948.
87. Sun Z., Milos P.M., Thompson J.F., Lloyd D.B., Mank-Seymour A., Richmond J., Corde J.S., Zhou J. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J. Mol. Cell. Cardiol. 2004, 37:1031-1039.
88. Hajj A., Ksouda K., Peoc'h K., Curis E., Messali A., Deveaux L.L., Bloch V., Prince N., Mouly S., Scherrmann J.M., Lépine J.P., Laplanche J.L., Drici M.D., Vorspan F. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug Alcohol Depend. 2014, 141:34-38.
89. Anchersen K., Hansteen V., Gossop M., Clausen T., Waal H. Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend. 2010, 112:216-219.
90. Hayashi K., Shimizu M., Ino H., Yamaguchi M., Terai H., Hoshi N., Higashida H., Terashima N., Uno Y., Kanaya H., Mabuchi H. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the Nterminus of HERG. Clin. Sci. (Lond.) 2004, 107:175-182.
91. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkela E., Hyttinen J., Kontula K., Swan H., Conklin B.R., Yamanaka S., Silvennoinen O., Aalto-Setala K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 2011, 5:220-230.
92. + channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation 2002, 105:2830-2835.
93. Ganapathi S.B., Kester M., Elmslie K.S. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am. J. Physiol. Cell Physiol. 2009, 296:C701-C710.
94. Parkman H.P., Jacobs M.R., Mishra A., Hurdle J.A., Sachdeva P., Gaughan J.P., Krynetskiy E. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig. Dis. Sci. 2011, 56:115-124.
95. Liu X., Limberis J.T., Su Z., Houseman K., Diaz G.J., Gintant G.A., Cox B.F., Martin R.L. Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. Life Sci. 2012, 90:607-611.
96. Perry M., Sanguinetti M., Mitcheson J. Symposium review: revealing the structural basis of action of hERG potassium channel activators and blockers. J. Physiol. 2010, 588:3157-3167.
97. + channel radioligand binding assays reveal allosteric characteristics of dofetilide analogs. Toxicol. Appl. Pharmacol. 2014, 274:78-86.
98. Milnes J.T., Dempsey C.E., Ridley J.M., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett. 2003, 547:20-26.
99. + channels. J. Gen. Physiol. 2003, 121:583-598.
100. Bril A., Gout B., Bonhomme M., Landais L., Faivre J.F., Linee P., Poyser R.H., Ruffolo R.R. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J. Pharmacol. Exp. Ther. 1996, 276:637-646.
101. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 2004, 43:369-379.
102. Hoffmann P., Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 2006, 53:87-105.
103. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:439-447.
104. Lee H., Kim K.S., Park S.J., Kim E.J. Cellular mechanism of the QT prolongation induced by sulpiride. Int. J. Toxicol. 2009, 28:207-212.
105. Obiol-Pardo C., Gomis-Tena J., Sanz F., Saiz J., Pastor M. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J. Chem. Inf. Model. 2011, 51:483-492.
106. Wiśniowska B., Mendyk A., Szlek J., Kołaczkowski M., Polak S.J. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents. Appl. Toxicol. Jan 5 2015, [Epub ahead of print]. 10.1002/jat.3095.
107. Moller C., Witchel H. Automated electrophysiology makes the pace for cardiac ion channel safety screening. Front. Pharmacol. 2011, 2:73.
108. Di Veroli G.Y., Davies M.R., Zhang H., Abi-Gerges N., Boyett M.R. High throughput screening of drug-binding dynamics to HERG improves drug safety assessment. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H104-H117.
109. Mirams G.R., Cui Y., Sher A., Fink M., Cooper J., Heath B.M., McMahon N.C., Gavaghan D.J., Noble D. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 2011, 91:53-61.
110. Davies M.R., Mistry H.B., Hussein L., Pollard C.E., Valentin J.P., Swinton J., Abi-Gerges N. An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H1466-H1480.
111. Kramer J., Obejero-Paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S., Brown A.M. MICE models: superior to the hERG model in predicting Torsade de Pointes. Sci. Rep. 2013, 3:2100.
112. Nogawa H., Kawai T. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia. Eur. J. Pharmacol. 2014, 14:495-496.
113. Dennis A.T., Wang L., Wan H., Nassal D., Deschenes I., Ficker E. Molecular determinants of pentamidine-induced hERG trafficking inhibition. Mol. Pharmacol. 2012, 81:198-209.
114. Ficker E., Kuryshev Y.A., Dennis A.T., Obejero-Paz C., Wang L., Hawryluk P., Wible B.A., Brown A.M. Mechanisms of arsenic induced prolongation of cardiac repolarization. Mol. Pharmacol. 2004, 66:33-44.
115. Ficker E., Dennis A.T., Wang L., Brown A.M. Role of the cytosolic chaperones Hsp70 and Hsp90 inmaturation of the cardiac potassium channel hERG. Circ. Res. 2003, 92:e87-e100.
116. Varkevisser R., Houtman M.J., Linder T., deGit K.C., Beekman H.D., Tidwell R.R., Ijzerman A.P., Stary-Weinzinger A., Vos M.A., vanderHeyden M.A. Structure-activity relationships of pentamidine affected ion channel trafficking and dofetilide mediated rescue. Br. J. Pharmacol. 2013, 169:1322-1334.
117. Guo J., Li X., Shallow H., Xu J., Yang T., Massaeli H., Li W., Sun T., Pierce G.N., Zhang S. Involvement of caveolin in probucol induced reduction in hERG plasma-membrane expression. Mol. Pharmacol. 2011, 79:806-813.
118. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., Brown A.M. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 2005, 52:136-145.
119. Babcock J.J., Du F., Xu K., Wheelan S.J., Li M. Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors. PLoS One 2013, 8:e69513.
120. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes and disease. Science 2006, 313:1929-1935.
121. Towart R., Linders J.T.M., Hermans An H., Rohrbacher J., van der Linde H.J., Ercken M., Cik M., Roevens P., Teisman A., Gallacher D.J. Blockade of the IKs potassium channel: an overlooked cardiovascular liability in drug safety screening?. J. Pharmacol. Toxicol. Methods 2009, 60:1-10.
122. Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., Sridhar A. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 2013, 134:412-426.
123. Navarrete E.G., Liang P., Lan F., Sanchez-Freire V., Simmons C.S., Gong T., Sharma A., Burridge P.W., Patlolla B., Lee A.S., Wu H., Beygui R.E., Wu S.M., Robbins R.C., Bers D.M., Wu J.C. Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013, 128:S3-S13.
124. Sager P.T., Gintant G., Turner J.R., Pettit S., Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 2014, 167:292-300.
125. Cavalli A., Poluzzi E., De Ponti F., Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 2002, 45:3844-3853.
126. Roche O., Trube G., Zuegge J., Pflimlin P., Alanine A., Schneider G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. ChemBioChem 2002, 3:455-459.
127. Bains W., Basman A., White C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol. 2004, 86:205-233.
128. Yap C.W., Cai C.Z., Xue Y., Chen Y.Z. Prediction of torsade causing potential of drugs by support vector machine approach. Toxicol. Sci. 2004, 79:170-177.
129. + blocking potency: application of structural knowledge. SAR QSAR Environ. Res. 2004, 15:399-411.
130. Tobita M., Nishikawa T., Nagashima R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:2886-2890.
131. Cianchetta G., Li Y., Kang J., Rampe D., Fravolini A., Cruciani G., Vaz R.J. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett. 2005, 15:3637-3642.
132. Yoshida K., Niwa T. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J. Chem. Inf. Model. 2006, 46:1371-1378.
133. Seierstad M., Agrafiotis D.K. A QSAR model of HERG binding using a large, diverse, and internally consistent training set. Chem. Biol. Drug Des. 2006, 67:284-296.
134. Bhavani S., Nagargadde A., Thawani A., Sridhar V., Chandra N. Substructure-based support vector machine classifiers for prediction of adverse effects in diverse classes of drugs. J. Chem. Inf. Model. 2006, 46:2478-2486.
135. Coi A., Massarelli I., Murgia L., Saraceno M., Calderone V., Bianucci A.M. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg. Med. Chem. 2006, 14:3153-3159.
136. Dubus E., Ijjaali I., Petitet F., Michel A. In silico classification of HERG channel blockers: a knowledge-based strategy. ChemMedChem 2006, 1:622-630.
137. Ekins S., Balakin K.V., Savchuk N., Ivanenkov Y. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. J. Med. Chem. 2006, 49:5059-5071.
138. Sun H. An accurate and interpretable Bayesian classification model for prediction of HERG liability. ChemMedChem 2006, 1:315-322.
139. Gepp M.M., Hutter M.C. Determination of hERG channel blockers using a decision tree. Bioorg. Med. Chem. 2006, 14:5325-5332.
140. Waring M.J., Johnstone C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 2007, 17:1759-1764.
141. Leong M.K. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability. Chem. Res. Toxicol. 2007, 20:217-226.
142. Obrezanova O., Csanyi G., Gola J.M., Segall M.D. Gaussian processes: a method for automatic QSAR modeling of ADME properties. J. Chem. Inf. Model. 2007, 47:1847-1857.
143. + current. J. Physiol. Sci. 2008, 58:459-470.
144. Jia L., Sun H. Support vector machines classification of hERG liabilities based on atom types. Bioorg. Med. Chem. 2008, 16:6252-6260.
145. Chekmarev D.S., Kholodovych V., Balakin K.V., Ivanenkov Y., Ekins S., Welsh W.J. Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem. Res. Toxicol. 2008, 21:1304-1314.
146. Thai K.M., Ecker G.F. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg. Med. Chem. 2008, 16:4107-4119.
147. Thai K.M., Ecker G.F. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers. Mol. Divers. 2009, 13:321-336.
148. Nisius B., Goller A.H. Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition. J. Chem. Inf. Model. 2009, 49:247-256.
149. Hansen K., Rathke F., Schroeter T., Rast G., Fox T., Kriegl J.M., Mika S. Bias-correction of regression models: a case study on hERG inhibition. J. Chem. Inf. Model. 2009, 49:1486-1496.
150. + channel blockers. Eur. J. Med. Chem. 2009, 44:1926-1932.
151. Su B.H., Shen M.Y., Esposito E.X., Hopfinger A.J., Tseng Y.J. In silico binary classification QSAR models based on 4D fingerprints and MOE descriptors for prediction of hERG blockage. J. Chem. Inf. Model. 2010, 50:1304-1318.
152. Hidaka S., Yamasaki H., Ohmayu Y., Matsuura A., Okamoto K., Kawashita N., Takagi T. Nonlinear classification of hERG channel inhibitory activity by unsupervised classification method. J. Toxicol. Sci. 2010, 35:393-399.
153. + channel blockers using GFA and HypoGen techniques. J. Mol. Graph. Model. 2008, 26:966-976.
154. Borosy A.P., Keseru K., Penzes I., Matyus P. 3D QSAR study of class I antiaarhythmics. J. Mol. Struct. 2000, 503:113-129.
155. Gunturi S.B., Archana K., Khandelwal A., Narayanan R. Prediction of hERG potassium channel blockade using kNN-QSAR and local lazy regression methods. QSAR Comb. Sci. 2008, 27:1305-1317.
156. Kramer C., Beck B., Kriegl J.M., Clark T. A composite model for HERG blockade. ChemMedChem 2008, 3:254-265.
157. Fenu L.A., Teisman A., De Buck S.S., Sinha V.K., Gilissen R.A.H.J., Nijsen M.J.M.A., Mackie C.E., Sanderson W.E. Cardiovascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay. J. Comput. Aided Mol. Des. 2009, 23:883-895.
158. Robinson R.L.M., Glen R.C., Mitchell J.B.O. Development and comparison of hERG blocker classifiers: assessment on different datasets yields markedly different results. Mol. Inf. 2011, 30:443-458.
159. Sinha N., Sen S. Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. Eur. J. Med. Chem. 2011, 46:618-630.
160. Du-Cuny L., Chen L., Zhang S. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling. J. Chem. Inf. Model. 2011, 51:2948-2960.
161. Kim J.H., Chae C.H., Kang S.M., Lee J.Y., Lee G.N., Hwang S.H., Kang N.S. The predictive QSAR model for hERG inhibitors using Bayesian and random forest classification method. Bull. Kor. Chem. Soc. 2011, 32:1237-1240.
162. Su B.H., Tu Y., Esposito E.X., Tseng Y.J. Predictive toxicology modeling: protocols for exploring hERG classification and Tetrahymena pyriformis end point predictions. J. Chem. Inf. Model. 2012, 52:1660-1673.
163. Kar S., Roy K. Prediction of hERG potassium channel blocking actions using combination of classification and regression based models: a mixed descriptors approach. Mol. Inf. 2012, 31:879-894.
164. + channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. J. Mol. Model. 2012, 18:1023-1036.
165. Wang Z., Mussa H.Y., Lowe R., Glen R.C., Yan R.A. Probability Based hERG Blocker Classifiers. Mol. Inf. 2012, 31:679-685.
166. Pourbasheer E., Beheshti A., Khajehsharifi H., Ganjali M.R., Norouzi P. QSAR study on hERG inhibitory effect of kappa opioid receptor antagonists by linear and non-linear methods. Med. Chem. Res. 2013, 22:4047-4058.
167. Moorthy N.S.H.N., Ramos M.J., Fernandes P. a QSAR and pharmacophore analysis of a series of piperidinyl urea derivatives as HERG blockers and H3 antagonists. Curr. Drug Discov. Technol. 2013, 10:47-58.
168. Ruggiu F., Marcou F.G., Varnek A., Horvath D. Isida property-labelled fragment descriptors. Mol. Inf. 2010, 29:855-868.
169. Mirams G.R., Davies M.R., Brough S.J., Bridgland-Taylor M.H., Cui Y., Gavaghan D.J., Abi-Gerges N. Prediction of thorough QT study results using action potential simulations based on ion channel screens. J. Pharmacol. Toxicol. Methods 2014, 70:246-254.
170. Liu L.L., Lu J., Zheng M.Y., Luo X.M., Zhu W.L., Jiang H.L., Chen K.X. Novel Bayesian classification models for predicting compounds blocking hERG potassium channels. Acta Pharmacol. Sin. 2014, 35:1093-1102.
171. Shen M.Y., Su B.H., Esposito E.X., Hopfinger A.J., Tseng Y.J. A comprehensive support vector machine binary hERG classification model based on extensive but bias end point hERG data sets. Chem. Res. Toxicol. 2011, 24:934-949.
172. Kireeva N., Kuznetsov S.L., Bykov A.A., Tsivadze A.Y. Towards in silico identification of the human ether-a-go-go related gene channel blockers; discriminative vs. generative classification models. SAR QSAR Environ. Res. 2013, 24:103-117.
173. Yu P., Wild D.J. Fast rule-based bioactivity prediction using associative classification mining. J. Cheminform. 2012, 4:29.
174. Kratz J.M., Schuster D., Edtbauer M., Saxena P., Mair C.E., Kirchebner J., Matuszczak B., Baburin I., Hering S., Rollinger J.M. Experimentally validated hERG pharmacophore models as cardiotoxicity prediction tools. J. Chem. Inf. Model. 2014, 54:2887-2890.